Initial Public Reporting of Quality at Veterans Affairs vs Non-Veterans Affairs Hospitals
Recently, the Centers for Medicare and Medicaid (CMS) announced the inclusion of Veterans Affairs (VA) hospital performance data on its Hospital Compare website. 1 Prior to this release, comparisons of quality at VA vs non-VA hospitals were inconclusive and had methodological limitations. 2, 3 Given longstanding concerns about care at VA hospitals, 4 our objective was to compare available outcome, patient experience, and behavioral health measures between VA and non-VA hospitals.
Methods | Hospital-level data were obtained for 129 VA and 4010 non-VA hospitals through the CMS Hospital Compare website (reporting period spanned July 2012-March 2015) and were merged with 2014 American Hospital Association Annual Survey data. Non-VA hospitals were classified as major teaching (based on Council of Teaching Hospitals membership), other teaching, community, specialty, and critical access hospitals. t Tests with and without Bonferroni correction for multiple comparisons were used to evaluate pairwise comparisons between VA and non-VA hospitals for risk-adjusted rates of 17 outcome measures (9 Agency for Healthcare Research and Quality Patient Safety Indicators [PSIs], 4 mortality measures, 4 readmissions measures), 10 patient experience measures, and 9 behavioral health measures.
Results | Veterans Affairs hospitals had better outcomes than non-VA hospitals for 6 of 9 PSIs. There were no significant differences for the other 3 PSIs ( Table 1 ). In addition, VA hospitals had better outcomes for all the mortality and readmissions metrics (Table 1) . However, on the patient experience measures, non-VA hospitals scored better overall than VA hospitals for nursing and physician communication, responsiveness, quietness, pain management, and on whether the patient would recommend the hospital to others ( Table 2) . For behavioral health measures, non-VA hospitals did better on 4 of 9 measures, while VA hospitals did better on 1 of 9 measures ( Table 2) .
Discussion | In this evaluation of the most recent, comprehensive public reporting of VA hospital quality that can be compared with non-VA hospitals, we found that VA hospitals performed better than non-VA hospitals for most outcome measures, but VA hospitals performed worse on certain patient experience measures and behavioral health measures. A recent systematic review was inconclusive about the quality of care provided at VA hospitals vs non-VA hospitals. 3 In that analysis, VA hospitals generally performed better than non-VA hospitals with respect to safety and effectiveness of care; however, most of the studies in this review examined only a subset of patients, had a smaller sample size of non-VA Hospitals, used older data, and/or did not examine PSIs or the current patient experience metrics used by CMS. 3 There are several possible explanations for the findings in our study. First, the VA may have invested considerable efforts in quality improvement and care coordination over the last 3 decades. Second, they may also have better documentation of comorbidities that are used in the risk adjustment, as a result of the VA unified electronic health record system and because patients have their health care mostly within 1 system. 3 Third, while the mortality and readmission measures are thought to be indicative of quality, many of the Agency for Healthcare Research and Quality PSIs have been questioned due to the validity of the data (ie, complications are coded inconsistently, data are not audited) and due to ascertainment bias. 5 In fact, when ascertainment bias occurs, quality measures may reflect the inverse of quality, where hospitals performing worse may be the ones providing higher-quality care (eg, PS1-12 venous thromboembolism outcome measure). 6 While concerns remain about the validity of some of the measures used in current public reporting of health quality, the available data suggests that VA hospitals have a similar or more favorable quality compared with non-VA hospitals. On the other hand, these results suggest that VA hospitals should focus on improving certain aspects of patient experience and Letters behavioral health. Hospitals can use these data to identifyβ-Blockers are the most commonly used class of medication for treating cardiac conditions in pregnant women. 1 Despite the common use of this class of medication, data that support its safety are limited. β-Blockers cross the placenta and potentially can cause physiological changes in the fetus.
2 β-Blocker exposure has been shown to cause bradycardia and hypoglycemia in the neonate. 3 A recent meta-analysis 4 reported an association between β-blocker exposure and fetal congenital cardiovascular defects, raising a concern regarding potential teratogenic effects of this class of medication. This study examines the risk of fetal cardiac malformations in association with maternal β-blocker exposure.
Methods | This is a retrospective population-based cohort study that included births in the Kaiser Permanente Southern California (KPSC) Region between January 1, 2003, and December 31, 2014. Only singleton pregnancies were included. Pregnant women exposed to β-blockers during pregnancy were identified using pharmacy dispensing records. Maternal comorbidities and fetal congenital anomalies were identified by searching electronic medical records using ICD-9-CM codes. Fetal birth weights were obtained from California birth certificates. Logistic regression analyses were used to estimate odds ratios (ORs) with 95% CIs. Multivariable logistic regression models were constructed by including factors that have been shown in other studies to affect fetal congenital anomalies. The research protocol used in this study was reviewed and approved by the Kaiser Permanente institutional review board. The need for written informed consent was waived owing to the retrospective nature of the study.
Results | In a cohort of 379 238 pregnancies, 4847 (1.3%) were exposed to β-blockers. Among this group, 2628 (0.7%) were exposed to β-blockers during the first trimester of pregnancy. The 4 most commonly prescribed β-blockers were labetalol (n = 3357), atenolol (n = 638), propranolol (n = 489), and metoprolol (n = 324). Table 1 shows the baseline maternal characteristics of the study population. Women exposed to β-blockers were older, and had higher body mass indices. Diagnoses of hypertension, preeclampsia, eclampsia, hyperlipidemia, diabetes, heart failure, and a history of arrhythmia were more common among patients exposed to β-blockers. Gestational age at delivery was lower in the β-blocker-exposed group (mean [SD] weeks, β-blocker group 37.4 [3.0] vs 38.9 [1.9] in the unexposed group). Table 2 summarizes the unadjusted and adjusted associations between β-blocker exposure and congenital cardiac anomalies in the infants. In unadjusted analyses, maternal β-blocker exposure was associated with significantly increased odds of fetal congenital cardiac anomalies. However, after adjusting for maternal age, maternal body mass index, and maternal comorbidities, there was no longer an association between β-blocker exposure and fetal congenital cardiac anomalies. These results suggest that the associations seen in the unadjusted analysis were caused by confounders rather than effects conferred by β-blocker exposure itself.
Discussion | In this large population-based cohort study in California, we found that β-blocker exposure was not associated 
